171 results about "Prognosis biomarker" patented technology

The invention discloses application of HOXD1 in diagnosis, prognosis and treatment of liver cancer, and particularly relates to application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for diagnosing a liver cancer object. The invention discloses application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for prognosis of a liver cancer object. The invention discloses an application of HOXD1 as a target in screening medicines for treating liver cancer. The HOXD1 expression inhibitor is applied to preparation of a medicine for treating liver cancer. Differential expression of the HOXD1 in hepatocellular carcinoma tissues and normal hepatocellular carcinoma tissues is clear through research, high expression of the HOXD1 is closely related to the survival reduction period of clinical hepatocellular carcinoma patients, specific knock-down of the HOXD1 can obviously reduce the proliferation capacity of the hepatocellular carcinoma, and a new diagnosis / prognosis marker and a treatment target are provided for early discovery, early treatment and prognosis of the hepatocellular carcinoma. And a new treatment strategy and direction are provided.

The invention belongs to the field of biological medicine, and relates to application of bacteria as a marker for detection, treatment or prognosis of nasopharyngeal carcinoma. As a marker, the bacterium disclosed by the invention can be used for prevention, diagnosis, treatment and prognosis intervention of nasopharynx cancer. Through verification, the marker has relatively high diagnosis efficiency and accuracy on diagnosis and prognosis of nasopharynx cancer, an economical, simple and convenient solution is provided for clinic, and a new insight is also provided for accurate individualized treatment of nasopharynx cancer patients.

The invention belongs to the technical field of medical treatment, and particularly relates to a cancer prognosis marker screening method which comprises the following steps: step 1) acquiring an imaging mass spectrometry flow cytometry analysis data set; 2) performing single cell segmentation on the image in the imaging mass spectrometry flow cytometry analysis data set, and annotating the cell type of the single cell according to the expression intensity of the marker to be screened; 3) identifying an area where the epithelial cells, the immune cells and the fibrotic cells intersect, and obtaining marker expression intensity in the area where the epithelial cells, the immune cells and the fibrotic cells intersect; 4) obtaining an intercellular interaction analysis result based on the cell frequency and the marker expression intensity, and 5) performing regression analysis according to the cell frequency, the marker expression intensity and the intercellular interaction result in different comparison groups, and screening to obtain the prognostic marker.

The invention belongs to the technical field of biological medicine and molecular biology, and relates to application of TRIM38 as a therapeutic target and a prognostic marker of breast cancer. Research accidentally finds that TRIM38 can inhibit proliferation and metastasis of breast cancer, and further research shows that TRIM38 can block autophagy flow of breast cancer cells. Meanwhile, the TRIM38 can have a combined anti-tumor effect with autophagy inhibitors such as hydroxychloroquine and the like. In addition, the research shows that the TRIM38 can also be used as a prognostic marker of a breast cancer patient.

The invention provides a gastric cancer prognosis marker and application thereof, and belongs to the technical field of biology. According to the invention, survival analysis is carried out to explore the prognosis correlation of m6A'write 'RBM15 in gastric cancer. The result proves that the RBM15 is a prognostic marker related to a better clinical result and can be used for judging the prognosis condition of a gastric cancer patient. The invention verifies the relationship among RBM15, ECT2 and EMT signal pathway, and the result proves that RBM15 mediates m6A methylation of ECT2 through IGF2BP3, affects the stability of ECT2 RNA, affects the expression of ECT2, and regulates EMT signal pathway at the same time. The invention further discloses a mechanism of the RBM15 for influencing proliferation, invasion and migration of gastric cancer cells and sensitivity to 5-fluorouracil chemotherapy, and a new therapeutic target is provided for gastric cancer treatment.

The invention provides an application of CCPG1 as a molecular marker in preparation of a product for diagnosis or prognosis of bladder cancer, and it is found for the first time that the CCPG1 gene has significant high expression in bladder cancer and can be used for early diagnosis of bladder cancer; and the highly expressed CCPG1 gene is closely related to poor prognosis of bladder cancer, which prompts that the CCPG1 gene can be used as a prognosis marker, and provides effective information for early diagnosis, prognosis evaluation and treatment effect monitoring of bladder cancer. The expression level of CCPG1 in tissue of a patient can be detected, so that a cystacarcinoma patient and a normal control person can be quickly and conveniently distinguished, the sensitivity reaches 85% or above, and the specificity reaches 70% or above.

The invention discloses application of a prognostic marker H4K5la in prognostic evaluation of neuroblastoma, and relates to the technical field of biology. The invention provides application of the H4K5la detection reagent in preparation of products for judging prognosis of neuroblastoma, prognosis evaluation accuracy is improved by detecting the expression level of H4K5la, the detection cost is reduced by the detection method, detection sensitivity and specificity are enhanced, a theoretical basis is provided for a treatment intervention strategy of targeted H4K5la, and the application of the H4K5la detection reagent in preparation of products for judging prognosis of neuroblastoma is provided. Important reference can be provided for further treatment development.

A prognostic risk score for chemotherapy-sensitive cancers, particularly acute myeloid leukemia (AML), is based on somatic genetic abnormalities affecting specific genes in the mitochondrial genome.

The invention belongs to the field of biological medicine, and relates to application of thymidine-5 '-monophosphate as a colorectal cancer diagnosis and prognosis biomarker. Through comparison of omics data of intestinal flora metabolites of healthy people and colorectal cancer patients and in-vitro and in-vivo level verification, the potential of thymidine-5 '-monophosphate serving as the colorectal cancer diagnostic marker is screened out. Excrement samples needed for detection are easy to obtain, the compliance of patients is improved through non-invasive operation, and the early diagnosis rate of colorectal cancer is expected to be improved.

The present disclosure provides a new therapeutic target and marker, circBCO2, for inhibiting the progression of liver cancer, especially hepatocellular carcinoma. Inhibition of the expression of circBCO2 or destruction of the signal pathway regulated thereby can serve as a potential therapeutic target for inhibiting the progression of liver cancer. Meanwhile, circBCO2 can also serve as a marker, especially a prognostic marker, for HCC.

The invention relates to a nucleic acid aptamer for specifically recognizing a diagnosis and prognosis biomarker CHI3L1 of hepatic fibrosis and application of the nucleic acid aptamer. The nucleic acid aptamer is a nucleic acid aptamer CHI3L1-apt-1, and the nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO.1. The invention also provides application of the nucleic acid aptamer in preparation of a reagent, a kit or a sensor for detecting CHI3L1, and the like. The CHI3L1 is used as a diagnosis and prognosis biomarker of hepatic fibrosis, and the aptamer specifically bound with the CHI3L1 is screened out for the first time; the nucleic acid aptamer CHI3L1-apt-1 can be combined with CHI3L1 with high affinity and high specificity, the KD value of the nucleic acid aptamer CHI3L1-apt-1 is 28.7 nM, and the nucleic acid aptamer CHI3L1-apt-1 has application prospects in the aspects of liver fibrosis diagnosis and prognosis. The nucleic acid aptamer CHI3L1-apt-1 can be applied to separation and purification of CHI3L1, preparation of CHI3L1 detection reagents and development of drugs for treating CHI3L1 related diseases, and has wide application prospects and important scientific, social and economic values.

The invention relates to the field of biological medicine, in particular to application of LEPR gene or protein serving as a target in preparation of cholangiocarcinoma treatment products, the fact that LEPR can serve as a cholangiocarcinoma treatment target and a prognostic marker at the same time is found, and research shows that the expression level of LEPR is up-regulated to inhibit proliferation, migration and invasion of CCA cells, so that the cholangiocarcinoma treatment effect is improved, and the cholangiocarcinoma treatment effect is improved. Therefore, the LEPR can be used as an action target of the cholangiocarcinoma treatment medicine and is used for preparing or screening the cholangiocarcinoma treatment medicine.

The invention belongs to the technical field of biological medicine, and particularly discloses application of CCL28 as a biomarker and a therapeutic target in sepsis. The invention particularly relates to application of a CCL28 gene or a detection reagent for the expression quantity of the CCL28 gene in preparation of a kit for diagnosis or prognosis monitoring of sepsis. The expression of the novel immunomodulatory factor CCL28 in a sepsis patient is obviously improved, and the expression level of the novel immunomodulatory factor CCL28 is in obvious negative correlation with poor prognosis of sepsis. Through CLP induction of a sepsis mouse model, the invention finds that the expression level of CCL28 in sepsis mouse blood, abdominal cavity lavage fluid (PLF), liver and kidney is significantly increased. By adopting the recombinant CCL28 for treatment, the bacterial load in the mice with sepsis can be remarkably reduced, and the multi-organ injury of the mice with sepsis can be reduced, so that the survival rate of the mice with sepsis can be remarkably improved. In conclusion, the invention explores a novel immunomodulatory protein CCL28, and the novel immunomodulatory protein CCL28 not only can be used as a diagnosis and prognosis biomarker of sepsis, but also can be used as a novel target spot for treating sepsis.

Disclosed in the present invention is a use of an MP1 gene copy number variation detection reagent in preparation of an NK / T cell lymphoma prognosis kit. The present invention further provides a detection kit comprising the LMP1 gene copy number variation detection reagent, a use thereof, and an NK / T cell lymphoma prognosis method. In the present invention, a copy number variation event of LMP1 gene in an EB virus genome is used as a novel prognosis marker, which has a good prediction value for the overall survival and progression-free survival prognosis of an NK / T cell lymphoma patient, and can realize more accurate and effective prognostic assessment for the NK / T cell lymphoma patient.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

The invention relates to application of ADAMTS2 related to gastric cancer. The application comprises an application of the ADAMTS2 inhibitor in preparation of drugs for preventing, relieving and / or treating gastric cancer, an application of a reagent for detecting ADAMTS2 and / or COL3A1 in preparation of a kit or system for predicting gastric cancer prognosis, and a system or a prognosis instrument for predicting gastric cancer prognosis. The metalloproteinase ADAMTS2 is found to be remarkably and highly expressed in gastric cancer tissues and is associated with peritoneal metastasis and tumor dryness. Therefore, ADAMTS2 can be used as a diagnosis and prognosis marker and a treatment target of cervical cancer, and has a huge application prospect.

The invention discloses a prediction method of a protein biomarker based on SKCM prognosis and immunotherapy response. The prediction method comprises the following steps: S1, performing gene expression profile interaction analysis: S1, comparing expression levels of METTLs in SKCM and normal skin tissue by using online database gene expression profile interaction analysis; s2, analyzing prognosis by adopting a Kaplan-Meier curve; the invention relates to the technical field of biological detection. According to the prediction method of the protein biomarker based on SKCM prognosis and immunotherapy response, METTL9 expression up-regulation in SKCM tissue prompts poor prognosis, is closely related to tumor development and patient survival, and is expected to become a new therapeutic target; meanwhile, after immunotherapy, a patient with high expression of METTL9 has poor prognosis and poor reactivity to immunotherapy, so that a new method is provided for selecting a prognosis biomarker to predict the reactivity of SKCM to immunotherapy, and the survival condition of the SKCM patient can be predicted more accurately.

The application provides a molecular marker for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma and application thereof, and belongs to the technical field of biological detection. Through bioinformatics analysis methods such as multivariate statistical analysis, difference screening, single factor COX regression analysis and multi-factor COX regression analysis, the application obtains an adenine kinase 4 used for evaluating the prognosis marker of cervical squamous cell carcinoma and a brain sponge-shaped deformity 2 protein used for evaluating the prognosis biomarker of cervical adenocarcinoma. Based on the biomarkers of the application, a kit for evaluating cervical squamous cell carcinoma or adenocarcinoma is constructed, which is used for accurately evaluating the prognosis of cervical squamous cell carcinoma or adenocarcinoma.

The invention discloses application of circKIAA1617 serving as an ER < + > breast cancer treatment target and a prognostic marker. According to the invention, circKIAA1617 is found to be used as an ER + breast cancer diagnosis biomarker and a drug treatment target for the first time; experiments prove that in-vitro and in-vivo proliferation of ER + breast cancer cells can be inhibited by interfering expression of circKIAA1617, and proliferation and stemness progress of ER + breast cancer can be promoted by circKIAA1617; the circKIAA1617 can be used for promoting lipophagy of ER < + > breast cancer cells; therefore, the circKIAA1617 plays a role in promoting the cancer in the development of the ER + breast cancer.

The invention discloses an application of a TPM3P9 protein and an RBM4 protein in kidney cancer. According to the application disclosed by the invention, high expression of the RBM4 indicates better prognosis of a renal cancer patient, and the prognosis of the patient with low expression of the TPM3P9 and high expression of the RBM4 is the best, so that the RBM4 protein or the RBM4 protein and the TPM3P9 protein can be used as a clinical diagnosis or prognosis biomarker of the renal cancer. It is also found through experiments that proliferation and growth of kidney cancer cells can be regulated and controlled by regulating and controlling the expression quantity of the TPM3P9 protein, and therefore the RBM4 protein and the TPM3P9 protein can be combined to be used for developing drugs for treating kidney cancer or proliferation and growth of kidney cancer cells.

The present invention provides methods and composition for diagnosis, prognosis, prevention and / or treatment of cancers such as melanomas. The subject invention provides biomarkers (e.g., galectin-3 (Gal-3)) and methods for assessing the severity of a cancer / tumor and for monitoring the progressing of a cancer / tumor. The compositions according to the subject invention regulate and alter melanoma signaling, growth, and survival. The subject invention also provides molecular mechanisms governing melanoma metastasis to identify candidate diagnostic or prognostic markers and develop novel therapeutic opportunities. Further, the subject invention identifies the tumor-suppressive function of Gal-3 in melanoma cells, emphasizing the negative crosstalk between Gal-3 and NFAT1 and its role in dictating melanoma metastasis.

Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and / or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and / or to achieve complete remissions in patients with AML, including those with poor prognostic markers.

The invention discloses application of MISP as a breast cancer diagnosis / prognosis marker and a treatment target. The in-depth study on the expression of MISP in breast cancer cells and the influence on malignant biological behaviors such as breast cancer proliferation shows that compared with normal breast epithelial cells, the MISP is highly expressed in the breast cancer cells, the expression of the MISP is highly related to poor clinical prognosis of breast cancer patients, and the proliferation of the breast cancer cells can be inhibited by reducing the expression of the MISP. A new biomarker is provided for diagnosis and prognosis of the breast cancer, a new target spot is provided for treatment of the breast cancer, and important scientific significance is achieved in the aspects of subsequent drug research and development, clinical treatment and the like.

The invention discloses application of FBXO2 in treatment of prostatic cancer, and belongs to the field of prostatic cancer treatment. According to the application of the FBXO2 accelerant in preparation of the medicine for treating the prostatic cancer, specifically, expression of the FBXO2 in prostatic cancer tissue is remarkably reduced, and the high expression level of the FBXO2 is in positive correlation with good prognosis of a patient; fBXO2 overexpression can effectively inhibit prostate cancer cell proliferation and metastasis and induce apoptosis; mechanism research finds that FBXO2 is specifically combined with m6A reading protein YTHDF2 through a carboxyl terminal structural domain of the FBXO2, mediates the m6A reading protein YTHDF2 to generate ubiquitination modification at a K286 site and promotes proteasome dependent degradation of the m6A reading protein YTHDF2. The YTHDF2 is used as a high-expression cancer promoting protein in prostatic cancer, and the degradation of the YTHDF2 can be accelerated by regulating m6A methylation modification of CDKN1C mRNA, so that the tumor progression is driven. A theoretical basis is provided for developing a novel prognostic marker and a treatment strategy.

The application discloses a liver cancer prognosis marker and application thereof, and the liver cancer prognosis marker comprises TXNRD1, HAO1, C1S, OPTN and SNX6. The application provides a group of liver cancer prognosis markers, and a liver cancer patient prognosis prediction model is constructed based on the liver cancer prognosis markers. The liver cancer prognosis markers are obtained through comprehensive gene expression levels, single cell analysis and spatial transcriptome analysis, and the diversity of the data set and the large sample quantity improve the reliability and universality of the liver cancer prognosis markers and the liver cancer patient prognosis prediction model.

The invention provides a colorectum prognosis marker screening method and system, and relates to the technical field of data processing. The method comprises the following steps: collecting colorectum potential prognosis markers to form a colorectum potential prognosis set; collecting and screening crowd data, and performing classification division based on crowd sources to form different classified and screened crowd data; screening and analyzing all colorectal potential prognostic markers in the colorectal potential prognostic set according to diagnosis results for different classified screening population data to form prognostic marker screening data. According to the method, current possible markers are collected and reasonable analysis is carried out by using a proper diagnosis crowd, so that screening of a prognosis marker combination formed by a plurality of markers is realized, and a basis capable of reasonably carrying out colorectal prognosis analysis and judgment is formed.

The present invention belongs to the field of biotechnology and specifically relates to prognostic markers for multiple myeloma and their applications. In one aspect, the present invention provides the use of a reagent for detecting ATF4 in the preparation of a product for diagnosing multiple myeloma or predicting the prognosis of multiple myeloma patients. Preferably, the reagent for detecting ATF4 includes reagents required for detecting ATF4 protein expression levels, RPF content, or translation efficiency. In another aspect, the present invention also provides a system / device for achieving diagnosis and prognosis prediction.

A C1QBP protein can be used in preparation for an oral cancer screening or prognosis marker. A reagent for detecting a C1QBP protein expression level is in preparation for an oral cancer screening or prognosis kit. The C1QBP protein expression level in an oral mucosa tissue of a patient suffering from oral squamous cell carcinoma is found to be remarkably higher than that of a healthy patient. Using a reagent for detecting a C1QBP protein expression level for preparing a screening or prognosis kit of oral squamous cell carcinoma can realize effective screening or prognosis of oral squamous cell carcinoma.

The present invention relates to a method for assessing whether a subject diagnosed with acute myeloid leukemia (AML) will have a negative prognosis or a positive prognosis based on the expression level of SRRM2 on the cell surface of the mother cell of said subject, and the use of the expression level of SRRM2 on the cell surface of the mother cell as a prognostic marker of AML. The invention further relates to the medical use of SRRM2 targeted therapy for the treatment of SRRM2-positive AML patients.

The invention discloses a group of diagnosis, typing and prognostic markers for children Langerhans cell histocytosis, and belongs to the technical field of disease diagnosis. In the invention, an overall metabolic profile of bone marrow aspirates (BMA) of 34 children LCH patients is analyzed, and the patients are divided into three subtypes: single system diseases (SS), multi-system diseases (MS-RO-) without dangerous organ tiredness and multi-system diseases (MS-RO +) with dangerous organ tiredness. The metabonomics characteristics of children diagnosed as LCH are described, the metabolic characteristics of a multi-system LCH (MS-RO +) group with dangerous organs being tired before and after treatment are comprehensively researched, and important metabolic markers for molecular diagnosis, subtype classification, treatment evaluation and prognosis are provided for children patients suffering from LCH, especially high-risk LCH.